Clinical and economic implications of venous thromboembolism in pancreatic cancer patients: Evidence from the National Inpatient Sample.

667 Background: Venous thromboembolism (VTE) remains one of the most devastating complications of pancreatic cancer, often worsening clinical outcomes and straining healthcare resources. Despite its high prevalence and well-documented risks, comprehensive national-level data quantifying its impact remain limited, and implementation of systematic prevention strategies remains inconsistent in clinical practice. Methods: A retrospective analysis was performed using the 2021–2022 National Inpatient Sample (NIS). Adult hospitalizations with pancreatic cancer were identified by ICD-10 codes and stratified by the presence of VTE. Key outcomes included in-hospital mortality, use of critical care services, and total hospital charges. Multivariable logistic and linear regression models were used to evaluate associations, adjusting for demographics, insurance type, and hospital-location characteristics. Results: Among an estimated 46,031 pancreatic cancer hospitalizations, 8.8% were complicated by VTE. 19.3%, 31%, 33%, and 16.7% of the patients with pancreatic cancer were in age groups 18-59, 60-69, 70-79, and >80, respectively. 70% of these patients were White, while Black, Hispanic, and other races accounted for 13.8%, 9.1% and 7.1%, respectively. After adjusting for confounders, patients with VTE had 90% higher odds of in-hospital death (aOR 1.90, 95% CI 1.70-2.13; p